327 related articles for article (PubMed ID: 18461184)
1. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
[TBL] [Abstract][Full Text] [Related]
2. Driven by the same Ig enhancer and SV40 T promoter ras induced lung adenomatous tumors, myc induced pre-B cell lymphomas and SV40 large T gene a variety of tumors in transgenic mice.
Suda Y; Aizawa S; Hirai S; Inoue T; Furuta Y; Suzuki M; Hirohashi S; Ikawa Y
EMBO J; 1987 Dec; 6(13):4055-65. PubMed ID: 2832150
[TBL] [Abstract][Full Text] [Related]
3. Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Tran PT; Bendapudi PK; Lin HJ; Choi P; Koh S; Chen J; Horng G; Hughes NP; Schwartz LH; Miller VA; Kawashima T; Kitamura T; Paik D; Felsher DW
Sci Transl Med; 2011 Oct; 3(103):103ra99. PubMed ID: 21974937
[TBL] [Abstract][Full Text] [Related]
4. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
5. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
[TBL] [Abstract][Full Text] [Related]
6. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.
Fisher GH; Wellen SL; Klimstra D; Lenczowski JM; Tichelaar JW; Lizak MJ; Whitsett JA; Koretsky A; Varmus HE
Genes Dev; 2001 Dec; 15(24):3249-62. PubMed ID: 11751631
[TBL] [Abstract][Full Text] [Related]
7. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Degrassi A; Russo M; Nanni C; Patton V; Alzani R; Giusti AM; Fanti S; Ciomei M; Pesenti E; Texido G
Mol Cancer Ther; 2010 Mar; 9(3):673-81. PubMed ID: 20197397
[TBL] [Abstract][Full Text] [Related]
9. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
Goodrow T; Reynolds S; Maronpot R; Anderson M
Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
11. A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.
Haines BB; Bettano KA; Chenard M; Sevilla RS; Ware C; Angagaw MH; Winkelmann CT; Tong C; Reilly JF; Sur C; Zhang W
Neoplasia; 2009 Jan; 11(1):39-47. PubMed ID: 19107230
[TBL] [Abstract][Full Text] [Related]
12. Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele.
Wang Z; Feng Y; Bardeesy N; Wong KK; Liu XY; Ji H
PLoS One; 2012; 7(5):e37308. PubMed ID: 22606359
[TBL] [Abstract][Full Text] [Related]
13. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.
Karlsson A; Giuriato S; Tang F; Fung-Weier J; Levan G; Felsher DW
Blood; 2003 Apr; 101(7):2797-803. PubMed ID: 12517816
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice.
Zhuang S; Söderkvist P
Mutat Res; 2000 Jul; 452(1):19-26. PubMed ID: 10894886
[TBL] [Abstract][Full Text] [Related]
15. Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
Pan Y; Jiang Y; Tan L; Ravoori MK; Gagea M; Kundra V; Fischer SM; Yang P
Oncotarget; 2015 Nov; 6(36):38816-26. PubMed ID: 26452035
[TBL] [Abstract][Full Text] [Related]
16. Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.
Kortlever RM; Sodir NM; Wilson CH; Burkhart DL; Pellegrinet L; Brown Swigart L; Littlewood TD; Evan GI
Cell; 2017 Nov; 171(6):1301-1315.e14. PubMed ID: 29195074
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
18. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma.
Mainardi S; Mijimolle N; Francoz S; Vicente-Dueñas C; Sánchez-García I; Barbacid M
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):255-60. PubMed ID: 24367082
[TBL] [Abstract][Full Text] [Related]
19. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
20. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.
Jackson EL; Willis N; Mercer K; Bronson RT; Crowley D; Montoya R; Jacks T; Tuveson DA
Genes Dev; 2001 Dec; 15(24):3243-8. PubMed ID: 11751630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
